• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中枢神经系统疾病对药物向人脑细胞外和细胞内靶点输送的影响:一项“如果……会怎样”的模拟研究。

Impact of CNS Diseases on Drug Delivery to Brain Extracellular and Intracellular Target Sites in Human: A "WHAT-IF" Simulation Study.

作者信息

Saleh Mohammed A A, de Lange Elizabeth C M

机构信息

Division of Systems Biomedicine and Pharmacology, Leiden Academic Center for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands.

出版信息

Pharmaceutics. 2021 Jan 13;13(1):95. doi: 10.3390/pharmaceutics13010095.

DOI:10.3390/pharmaceutics13010095
PMID:33451111
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7828633/
Abstract

The blood-brain barrier (BBB) is equipped with unique physical and functional processes that control central nervous system (CNS) drug transport and the resulting concentration-time profiles (PK). In CNS diseases, the altered BBB and CNS pathophysiology may affect the CNS PK at the drug target sites in the brain extracellular fluid (brain) and intracellular fluid (brain) that may result in changes in CNS drug effects. Here, we used our human CNS physiologically-based PK model (LeiCNS-PK3.0) to investigate the impact of altered cerebral blood flow (CBF), tight junction paracellular pore radius (para), brain volume, and pH of brain (pH) and of brain (pH) on brain and brain PK for 46 small drugs with distinct physicochemical properties. LeiCNS-PK3.0 simulations showed a drug-dependent effect of the pathophysiological changes on the rate and extent of BBB transport and on brain and brain PK. Altered para, pH, and pH affected both the rate and extent of BBB drug transport, whereas changes in CBF and brain volume modestly affected the rate of BBB drug transport. While the focus is often on BBB paracellular and active transport processes, this study indicates that also changes in pH should be considered for their important implications on brain and brain target site PK.

摘要

血脑屏障(BBB)具有独特的物理和功能过程,可控制中枢神经系统(CNS)药物转运以及由此产生的浓度-时间曲线(PK)。在中枢神经系统疾病中,血脑屏障和中枢神经系统病理生理学的改变可能会影响脑细胞外液(脑)和细胞内液(脑)中药物靶点部位的中枢神经系统PK,这可能导致中枢神经系统药物效应的变化。在此,我们使用我们的基于人体中枢神经系统生理学的PK模型(LeiCNS-PK3.0),研究脑血流量(CBF)、紧密连接旁细胞孔半径(para)、脑体积以及脑(pH)和脑(pH)的改变对46种具有不同理化性质的小分子药物的脑和脑PK的影响。LeiCNS-PK3.0模拟显示,病理生理变化对血脑屏障转运速率和程度以及脑和脑PK具有药物依赖性效应。Para、pH和pH的改变影响血脑屏障药物转运的速率和程度,而CBF和脑体积的变化对血脑屏障药物转运速率有适度影响。虽然研究重点通常是血脑屏障的旁细胞和主动转运过程,但本研究表明,pH的变化因其对脑和脑靶点部位PK的重要影响也应予以考虑。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f153/7828633/d78f60168ced/pharmaceutics-13-00095-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f153/7828633/f4380cd137b3/pharmaceutics-13-00095-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f153/7828633/592d30a3befb/pharmaceutics-13-00095-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f153/7828633/d78f60168ced/pharmaceutics-13-00095-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f153/7828633/f4380cd137b3/pharmaceutics-13-00095-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f153/7828633/592d30a3befb/pharmaceutics-13-00095-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f153/7828633/d78f60168ced/pharmaceutics-13-00095-g003.jpg

相似文献

1
Impact of CNS Diseases on Drug Delivery to Brain Extracellular and Intracellular Target Sites in Human: A "WHAT-IF" Simulation Study.中枢神经系统疾病对药物向人脑细胞外和细胞内靶点输送的影响:一项“如果……会怎样”的模拟研究。
Pharmaceutics. 2021 Jan 13;13(1):95. doi: 10.3390/pharmaceutics13010095.
2
Using the LeiCNS-PK3.0 Physiologically-Based Pharmacokinetic Model to Predict Brain Extracellular Fluid Pharmacokinetics in Mice.使用 LeiCNS-PK3.0 生理基于的药代动力学模型预测小鼠脑细胞外液的药代动力学。
Pharm Res. 2023 Nov;40(11):2555-2566. doi: 10.1007/s11095-023-03554-5. Epub 2023 Jul 13.
3
Drug Distribution in Brain and Cerebrospinal Fluids in Relation to IC Values in Aging and Alzheimer's Disease, Using the Physiologically Based LeiCNS-PK3.0 Model.脑和脑脊液中药物分布与老化和阿尔茨海默病中 IC 值的关系,使用基于生理的 LeiCNS-PK3.0 模型。
Pharm Res. 2022 Jul;39(7):1303-1319. doi: 10.1007/s11095-022-03281-3. Epub 2022 May 23.
4
Does nonlinear blood-brain barrier transport matter for (lower) morphine dosing strategies?非线性血脑屏障转运对(较低)吗啡给药策略是否重要?
Eur J Pharm Sci. 2023 Aug 1;187:106482. doi: 10.1016/j.ejps.2023.106482. Epub 2023 May 27.
5
Exploring K values smaller than unity in remoxipride: A physiologically-based CNS model approach highlighting brain metabolism in drugs with passive blood-brain barrier transport.探索雷莫必利中小于 1 的 K 值:强调具有被动血脑屏障转运的药物中脑代谢的基于生理的中枢神经系统模型方法。
Eur J Pharm Sci. 2024 Dec 1;203:106883. doi: 10.1016/j.ejps.2024.106883. Epub 2024 Aug 22.
6
Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations.腰椎脑脊液到脑细胞外液替代是具有语境特异性的:来自 LeiCNS-PK3.0 模拟的见解。
J Pharmacokinet Pharmacodyn. 2021 Oct;48(5):725-741. doi: 10.1007/s10928-021-09768-7. Epub 2021 Jun 17.
7
The Extension of the LeiCNS-PK3.0 Model in Combination with the "Handshake" Approach to Understand Brain Tumor Pathophysiology.雷氏 CNS-PK3.0 模型的扩展与“握手”方法相结合,以了解脑肿瘤病理生理学。
Pharm Res. 2022 Jul;39(7):1343-1361. doi: 10.1007/s11095-021-03154-1. Epub 2022 Mar 7.
8
Revisiting Cerebrospinal Fluid Flow Direction and Rate in Physiologically Based Pharmacokinetic Model.重新审视基于生理药代动力学模型中的脑脊液流动方向和速率
Pharmaceutics. 2022 Aug 24;14(9):1764. doi: 10.3390/pharmaceutics14091764.
9
The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid.P-糖蛋白功能对脑脊髓液和脑细胞外液非稳态关系的影响。
J Pharmacokinet Pharmacodyn. 2013 Jun;40(3):327-42. doi: 10.1007/s10928-013-9314-4. Epub 2013 Mar 29.
10
Prediction of methotrexate CNS distribution in different species - influence of disease conditions.不同物种中甲氨蝶呤中枢神经系统分布的预测——疾病状态的影响。
Eur J Pharm Sci. 2014 Jun 16;57:11-24. doi: 10.1016/j.ejps.2013.12.020. Epub 2014 Jan 22.

引用本文的文献

1
Prediction of the Extent of Blood-Brain Barrier Transport Using Machine Learning and Integration into the LeiCNS-PK3.0 Model.使用机器学习预测血脑屏障转运程度并将其整合到LeiCNS-PK3.0模型中。
Pharm Res. 2025 Feb;42(2):281-289. doi: 10.1007/s11095-025-03828-0. Epub 2025 Feb 10.
2
'Comprehensive review of emerging drug targets in traumatic brain injury (TBI): challenges and future scope.创伤性脑损伤(TBI)中新兴药物靶点的全面综述:挑战与未来前景。
Inflammopharmacology. 2024 Oct;32(5):3271-3293. doi: 10.1007/s10787-024-01524-w. Epub 2024 Jul 17.
3
CNS Viral Infections-What to Consider for Improving Drug Treatment: A Plea for Using Mathematical Modeling Approaches.

本文引用的文献

1
Manipulating extracellular tumour pH: an effective target for cancer therapy.调控细胞外肿瘤pH值:癌症治疗的有效靶点。
RSC Adv. 2018 Jun 19;8(39):22182-22192. doi: 10.1039/c8ra02095g. eCollection 2018 Jun 13.
2
Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations.腰椎脑脊液到脑细胞外液替代是具有语境特异性的:来自 LeiCNS-PK3.0 模拟的见解。
J Pharmacokinet Pharmacodyn. 2021 Oct;48(5):725-741. doi: 10.1007/s10928-021-09768-7. Epub 2021 Jun 17.
3
Correction: Brain interstitial pH changes in the subacute phase of hypoxic-ischemic encephalopathy in newborn pigs.
中枢神经系统病毒感染——改善药物治疗需要考虑的因素:呼吁采用数学建模方法。
CNS Drugs. 2024 May;38(5):349-373. doi: 10.1007/s40263-024-01082-3. Epub 2024 Apr 5.
4
Interspecies Brain PBPK Modeling Platform to Predict Passive Transport through the Blood-Brain Barrier and Assess Target Site Disposition.种间脑PBPK建模平台,用于预测通过血脑屏障的被动转运并评估靶位点处置情况。
Pharmaceutics. 2024 Feb 4;16(2):226. doi: 10.3390/pharmaceutics16020226.
5
Strategies for Drug Delivery into the Brain: A Review on Adenosine Receptors Modulation for Central Nervous System Diseases Therapy.药物递送至大脑的策略:关于腺苷受体调节用于中枢神经系统疾病治疗的综述
Pharmaceutics. 2023 Oct 10;15(10):2441. doi: 10.3390/pharmaceutics15102441.
6
The Extension of the LeiCNS-PK3.0 Model in Combination with the "Handshake" Approach to Understand Brain Tumor Pathophysiology.雷氏 CNS-PK3.0 模型的扩展与“握手”方法相结合,以了解脑肿瘤病理生理学。
Pharm Res. 2022 Jul;39(7):1343-1361. doi: 10.1007/s11095-021-03154-1. Epub 2022 Mar 7.
7
Understanding the Blood-Brain Barrier and Beyond: Challenges and Opportunities for Novel CNS Therapeutics.了解血脑屏障及其他:新型中枢神经系统治疗药物的挑战与机遇。
Clin Pharmacol Ther. 2022 Apr;111(4):758-773. doi: 10.1002/cpt.2545. Epub 2022 Feb 27.
8
In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition.体外到体内外推与基于生理的药代动力学模型相关联,用于评估脑内药物处置。
AAPS J. 2022 Jan 13;24(1):28. doi: 10.1208/s12248-021-00675-w.
9
Understanding Drug Delivery to the Brain Using Liposome-Based Strategies: Studies that Provide Mechanistic Insights Are Essential.利用脂质体策略了解药物向大脑的传递:提供机制见解的研究至关重要。
AAPS J. 2021 Oct 28;23(6):114. doi: 10.1208/s12248-021-00648-z.
10
Translational CNS Steady-State Drug Disposition Model in Rats, Monkeys, and Humans for Quantitative Prediction of Brain-to-Plasma and Cerebrospinal Fluid-to-Plasma Unbound Concentration Ratios.用于定量预测脑-血浆和脑脊髓液-血浆未结合浓度比的大鼠、猴子和人类中枢神经系统稳态药物处置模型的转化。
AAPS J. 2021 Jun 3;23(4):81. doi: 10.1208/s12248-021-00609-6.
更正:新生猪缺氧缺血性脑病亚急性期脑间质pH值变化
PLoS One. 2020 Oct 8;15(10):e0240643. doi: 10.1371/journal.pone.0240643. eCollection 2020.
4
Structure, Function, and Regulation of the Blood-Brain Barrier Tight Junction in Central Nervous System Disorders.中枢神经系统疾病中血脑屏障紧密连接的结构、功能及调控
Front Physiol. 2020 Aug 6;11:914. doi: 10.3389/fphys.2020.00914. eCollection 2020.
5
Normal brain aging and Alzheimer's disease are associated with lower cerebral pH: an in vivo histidine H-MR spectroscopy study.正常脑老化和阿尔茨海默病与较低的脑内pH值相关:一项体内组氨酸氢磁共振波谱研究。
Neurobiol Aging. 2020 Mar;87:60-69. doi: 10.1016/j.neurobiolaging.2019.11.012. Epub 2019 Nov 22.
6
CNS Penetration of Cyclophosphamide and Metabolites in Mice Bearing Group 3 Medulloblastoma and Non-Tumor Bearing Mice.CNS 穿透性:携带第 3 组髓母细胞瘤的小鼠与非荷瘤小鼠的环磷酰胺及其代谢产物。
J Pharm Pharm Sci. 2019;22(1):612-629. doi: 10.18433/jpps30608.
7
The Blood-Brain Barrier and Its Intercellular Junctions in Age-Related Brain Disorders.《衰老相关脑疾病中的血脑屏障及其细胞间连接》
Int J Mol Sci. 2019 Nov 3;20(21):5472. doi: 10.3390/ijms20215472.
8
Heterogeneous drug tissue binding in brain regions of rats, Alzheimer's patients and controls: impact on translational drug development.大鼠、阿尔茨海默病患者和对照脑区的药物组织结合的异质性:对转化药物开发的影响。
Sci Rep. 2019 Mar 29;9(1):5308. doi: 10.1038/s41598-019-41828-4.
9
Altered grey matter volume, perfusion and white matter integrity in very low birthweight adults.极低出生体重儿成人的灰质体积、灌注和白质完整性改变。
Neuroimage Clin. 2019;22:101780. doi: 10.1016/j.nicl.2019.101780. Epub 2019 Mar 15.
10
Selective loss of cortical endothelial tight junction proteins during Alzheimer's disease progression.阿尔茨海默病进展过程中皮质内皮紧密连接蛋白的选择性丢失。
Brain. 2019 Apr 1;142(4):1077-1092. doi: 10.1093/brain/awz011.